US2012252840A1PendingUtilityA1

Method of Treating Cancer

61
Assignee: AFTAB DANA TPriority: Apr 4, 2011Filed: Apr 4, 2012Published: Oct 4, 2012
Est. expiryApr 4, 2031(~4.7 yrs left)· nominal 20-yr term from priority
A61K 31/47A61P 35/00A61P 35/04
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.

Claims

exact text as granted — not AI-modified
1 . A method for treating melanoma, comprising administering to a patient in need of such treatment a compound of Formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 R 1  is halo; 
 R 2  is halo; 
 R 3  is (C 1 -C 6 )alkyl; 
 R 4  is (C 1 -C 6 )alkyl; and 
 Q is CH or N. 
 
     
     
         2 . The method of  claim 1 , wherein the melanoma is ocular melanoma. 
     
     
         3 . The method of  claim 1 , wherein the ocular melanoma is choroidal or iris melanoma. 
     
     
         4 . The method of  claim 1 , wherein, the dual MET and VEGF modulator is a compound of Formula Ia: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 R 1  is halo; 
 R 2  is halo; and 
 Q is CH or N. 
 
     
     
         5 . The method of  claim 1 , wherein the compound of Formula I is Compound 1: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 5 , wherein Compound 1 is the (L)- or (D)-malate salt. 
     
     
         7 . The method of  claim 6 , wherein Compound 1 is in the crystalline N-1 form. 
     
     
         8 . The method of  claim 1 , wherein the compound of Formula I, I(a), or Compound 1, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent. 
     
     
         9 . A method for treating ocular melanoma comprising administering to a patient in need of such treatment Compound 1 or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.